Eli Lilly plans to invest $27 billion to bolster its domestic medicine production across several therapeutic areas by building four new manufacturing sites in the US.
Climate change, energy crisis, the call for a more environmentally compatible production method and socially responsible action do not stop at the pharmaceutical and biotech industries. Sustainability is becoming a central competitive and reputation factor and carries a high economic value. This need not be to the industry´s disadvantage. It helps companies to make processes more efficient, reduces energy consumption and keeps costs in check. But is the pharmaceutical industry already doing enough in this regard?
Genentech, the US biotech arm of Swiss pharma giant Roche, is building a new small-batch biologics manufacturing facility at its Oceanside campus in California, USA. Groundbreaking took place on Feb. 10.
Pfizer is planning to invest $750 million in its Kalamazoo County, Michigan, production site – one of its biggest – to increase output of injectables and vaccines, including the investigational mRNA flu shot currently in Phase 3 clinical trials.
